Skip to main content

Table 1 Demographic features of the study populations

From: Cross-sectional and longitudinal characterization of SCD patients recruited from the community versus from a memory clinic: subjective cognitive decline, psychoaffective factors, cognitive performances, and atrophy progression over time

 

HC

SCD-community

SCD-clinic

ANOVAs, p value

N

28

23

27

 

Female % (N)

46 (13)

61 (14)

41 (11)

(χ2) NS¤

Age

72.25 ± 6.33

71.70 ± 6.60

68.30 ± 7.99

0.09

Level of education

11.50 ± 3.64

12.65 ± 4.13

12.85 ± 3.60

0.37

MMSE

28.68 ± 1.09

28.70 ± 1.18

28.70 ± 1.27

0.99

DRS

0.05 ± 1.02

0.08 ± 0.58

−0.12 ± 0.90

0.68

ESR

− 0 ± 0.71

0.01 ± 0.72

− 0.49 ± 1.70

0.18

APOE ε4 (carrier) % (N)

18 (5)

26 (6)

15 (4)

(χ2) NS¤

Amyloid status (pos) % (N)

22 (6)

45 (10)

33 (9)

(χ2) NS¤

SUVr

0.97 ± 0.17

1.03 ± 0.18

1.01 ± 0.19

0.46

  1. Values indicate mean ± SD or percentage. When the analyses of variance (ANOVAs) reached significance, Newman-Keuls tests were used. ¤For gender, HC – SCD-community p = 0.29, HC – SCD-clinic p = 0.71, SCD-community – SCD-clinic p = 0.16; for APOE4 carrier: HC – SCD-community p = 0.49, HC – SCD-clinic p = 0.76, SCD-community – SCD-clinic p = 0.33; for amyloid status: HC – SCD-community 0.09, HC – SCD-clinic p = 0.37, SCD-community – SCD-clinic p = 0.39
  2. Abbreviations: APOE ε4 apolipoprotein E allele 4, DRS w-score of Mattis Dementia Rating Scale, ESR w-score of Encoding, Storage and Recuperation, HC healthy control, MMSE Mini-Mental State Examination, N sample size, NS not significant, pos positive, SCD subjective cognitive decline, SD standardized deviation